Pendleton seems to be a reasonable control, since the reported prevalence of 0.21% in patients under 60 matches other large data sets like the UK (0.25%).
https://www.parkinsons.org.uk/sites/default/files/2018-01/Pr...
https://www.parkinsons.org.uk/sites/default/files/2018-01/Pr...